Cargando…

Impact of a Publicly-Funded Pharmacare Program on Prescription Stimulant use Among Children and Youth: A Population-Based Observational Natural Experiment

OBJECTIVE: Stimulants are first-line pharmacotherapy for individuals with attention-deficit hyperactivity disorder. However, disparities in drug coverage may contribute to inequitable treatment access. In January 2018, the government of Ontario, Canada, implemented a publicly-funded program (OHIP+)...

Descripción completa

Detalles Bibliográficos
Autores principales: Antoniou, Tony, McCormack, Daniel, Kitchen, Sophie, Pajer, Kathleen, Gardner, William, Lunsky, Yona, Penner, Melanie, Tadrous, Mina, Mamdani, Muhammad, Juurlink, David N., Gomes, Tara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590092/
https://www.ncbi.nlm.nih.gov/pubmed/37016841
http://dx.doi.org/10.1177/07067437231166836
_version_ 1785123925954396160
author Antoniou, Tony
McCormack, Daniel
Kitchen, Sophie
Pajer, Kathleen
Gardner, William
Lunsky, Yona
Penner, Melanie
Tadrous, Mina
Mamdani, Muhammad
Juurlink, David N.
Gomes, Tara
author_facet Antoniou, Tony
McCormack, Daniel
Kitchen, Sophie
Pajer, Kathleen
Gardner, William
Lunsky, Yona
Penner, Melanie
Tadrous, Mina
Mamdani, Muhammad
Juurlink, David N.
Gomes, Tara
author_sort Antoniou, Tony
collection PubMed
description OBJECTIVE: Stimulants are first-line pharmacotherapy for individuals with attention-deficit hyperactivity disorder. However, disparities in drug coverage may contribute to inequitable treatment access. In January 2018, the government of Ontario, Canada, implemented a publicly-funded program (OHIP+) providing universal access to medications at no cost to children and youth between the ages of 0 and 24. In April 2019, the program was amended to cover only children and youth without private insurance. We studied whether these policy changes were associated with changes in prescription stimulant dispensing to Ontario children and youth. METHODS: We conducted a population-based observational natural experiment study of stimulant dispensing to children and youth in Ontario between January 2013 and March 2020. We used interventional autoregressive integrated moving average models to estimate the association between OHIP+ and its subsequent modification with stimulant dispensing trends. RESULTS: The implementation of OHIP+ was associated with a significant immediate increase in the monthly rate of stimulant dispensing of 53.6 individuals per 100,000 population (95% confidence interval [CI], 36.8 to 70.5 per 100,000) and a 14.2% (95% CI, 12.8% to 15.6%) relative percent increase in stimulant dispensing rates between December 2017 and March 2019 (1198.6 vs. 1368.7 per 100,000 population). The April 2019 OHIP+ program amendment was associated with an increase in monthly stimulant dispensing trends of 10.2 individuals per 100,000 population (95% CI, 5.0 to 15.5), with rates increasing 7.5% (95% CI, 6.2% to 8.7%) between March 2019 and March 2020 (1368.7 vs. 1470.8 per 100,000 population). These associations were most pronounced among males, children and youth living in the highest income neighbourhoods and individuals aged 20 to 24. CONCLUSION: A publicly-funded pharmacare program was associated with more children and youth being dispensed stimulants.
format Online
Article
Text
id pubmed-10590092
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-105900922023-10-22 Impact of a Publicly-Funded Pharmacare Program on Prescription Stimulant use Among Children and Youth: A Population-Based Observational Natural Experiment Antoniou, Tony McCormack, Daniel Kitchen, Sophie Pajer, Kathleen Gardner, William Lunsky, Yona Penner, Melanie Tadrous, Mina Mamdani, Muhammad Juurlink, David N. Gomes, Tara Can J Psychiatry Original Research OBJECTIVE: Stimulants are first-line pharmacotherapy for individuals with attention-deficit hyperactivity disorder. However, disparities in drug coverage may contribute to inequitable treatment access. In January 2018, the government of Ontario, Canada, implemented a publicly-funded program (OHIP+) providing universal access to medications at no cost to children and youth between the ages of 0 and 24. In April 2019, the program was amended to cover only children and youth without private insurance. We studied whether these policy changes were associated with changes in prescription stimulant dispensing to Ontario children and youth. METHODS: We conducted a population-based observational natural experiment study of stimulant dispensing to children and youth in Ontario between January 2013 and March 2020. We used interventional autoregressive integrated moving average models to estimate the association between OHIP+ and its subsequent modification with stimulant dispensing trends. RESULTS: The implementation of OHIP+ was associated with a significant immediate increase in the monthly rate of stimulant dispensing of 53.6 individuals per 100,000 population (95% confidence interval [CI], 36.8 to 70.5 per 100,000) and a 14.2% (95% CI, 12.8% to 15.6%) relative percent increase in stimulant dispensing rates between December 2017 and March 2019 (1198.6 vs. 1368.7 per 100,000 population). The April 2019 OHIP+ program amendment was associated with an increase in monthly stimulant dispensing trends of 10.2 individuals per 100,000 population (95% CI, 5.0 to 15.5), with rates increasing 7.5% (95% CI, 6.2% to 8.7%) between March 2019 and March 2020 (1368.7 vs. 1470.8 per 100,000 population). These associations were most pronounced among males, children and youth living in the highest income neighbourhoods and individuals aged 20 to 24. CONCLUSION: A publicly-funded pharmacare program was associated with more children and youth being dispensed stimulants. SAGE Publications 2023-04-05 2023-11 /pmc/articles/PMC10590092/ /pubmed/37016841 http://dx.doi.org/10.1177/07067437231166836 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Antoniou, Tony
McCormack, Daniel
Kitchen, Sophie
Pajer, Kathleen
Gardner, William
Lunsky, Yona
Penner, Melanie
Tadrous, Mina
Mamdani, Muhammad
Juurlink, David N.
Gomes, Tara
Impact of a Publicly-Funded Pharmacare Program on Prescription Stimulant use Among Children and Youth: A Population-Based Observational Natural Experiment
title Impact of a Publicly-Funded Pharmacare Program on Prescription Stimulant use Among Children and Youth: A Population-Based Observational Natural Experiment
title_full Impact of a Publicly-Funded Pharmacare Program on Prescription Stimulant use Among Children and Youth: A Population-Based Observational Natural Experiment
title_fullStr Impact of a Publicly-Funded Pharmacare Program on Prescription Stimulant use Among Children and Youth: A Population-Based Observational Natural Experiment
title_full_unstemmed Impact of a Publicly-Funded Pharmacare Program on Prescription Stimulant use Among Children and Youth: A Population-Based Observational Natural Experiment
title_short Impact of a Publicly-Funded Pharmacare Program on Prescription Stimulant use Among Children and Youth: A Population-Based Observational Natural Experiment
title_sort impact of a publicly-funded pharmacare program on prescription stimulant use among children and youth: a population-based observational natural experiment
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590092/
https://www.ncbi.nlm.nih.gov/pubmed/37016841
http://dx.doi.org/10.1177/07067437231166836
work_keys_str_mv AT antonioutony impactofapubliclyfundedpharmacareprogramonprescriptionstimulantuseamongchildrenandyouthapopulationbasedobservationalnaturalexperiment
AT mccormackdaniel impactofapubliclyfundedpharmacareprogramonprescriptionstimulantuseamongchildrenandyouthapopulationbasedobservationalnaturalexperiment
AT kitchensophie impactofapubliclyfundedpharmacareprogramonprescriptionstimulantuseamongchildrenandyouthapopulationbasedobservationalnaturalexperiment
AT pajerkathleen impactofapubliclyfundedpharmacareprogramonprescriptionstimulantuseamongchildrenandyouthapopulationbasedobservationalnaturalexperiment
AT gardnerwilliam impactofapubliclyfundedpharmacareprogramonprescriptionstimulantuseamongchildrenandyouthapopulationbasedobservationalnaturalexperiment
AT lunskyyona impactofapubliclyfundedpharmacareprogramonprescriptionstimulantuseamongchildrenandyouthapopulationbasedobservationalnaturalexperiment
AT pennermelanie impactofapubliclyfundedpharmacareprogramonprescriptionstimulantuseamongchildrenandyouthapopulationbasedobservationalnaturalexperiment
AT tadrousmina impactofapubliclyfundedpharmacareprogramonprescriptionstimulantuseamongchildrenandyouthapopulationbasedobservationalnaturalexperiment
AT mamdanimuhammad impactofapubliclyfundedpharmacareprogramonprescriptionstimulantuseamongchildrenandyouthapopulationbasedobservationalnaturalexperiment
AT juurlinkdavidn impactofapubliclyfundedpharmacareprogramonprescriptionstimulantuseamongchildrenandyouthapopulationbasedobservationalnaturalexperiment
AT gomestara impactofapubliclyfundedpharmacareprogramonprescriptionstimulantuseamongchildrenandyouthapopulationbasedobservationalnaturalexperiment